Porustobart + Pembrolizumab for Colon Cancer

This trial tests whether two medicines, porustobart and pembrolizumab (an immunotherapy drug), can treat microsatellite stable (MSS) colon cancer. The medicines aim to help the immune system fight the cancer before surgery. Researchers seek to determine the effectiveness of the medicines and their potential side effects. Participants will be divided into two groups, each receiving different schedules of the medicines, and must have colon cancer that can be surgically removed. This trial targets adults whose cancer hasn't spread and who can undergo surgery. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have taken an investigational agent within 3 weeks of the first dose or systemic corticosteroids within 1 week of the first dose, unless exceptions apply.

Research shows that pembrolizumab, a medicine in this trial, is generally safe. Past studies have demonstrated long-term benefits for some cancer types. Most patients tolerate it well, though some may experience side effects like tiredness, rash, or fever.

Less detailed safety information exists for porustobart, but it is being tested with pembrolizumab to enhance the immune system's fight against cancer. Since it is in a Phase 2 trial, earlier tests did not reveal major safety issues. This phase aims to provide more insight into how people react to the treatment and what side effects might occur.

Researchers are excited about Porustobart combined with Pembrolizumab for colon cancer because it offers a novel approach compared to standard treatments like chemotherapy and targeted therapies. Unlike most colon cancer treatments that usually focus on either killing cancer cells directly or blocking specific growth signals, Porustobart is designed to work synergistically with Pembrolizumab, an immunotherapy drug. This combination enhances the body's immune response against cancer cells more effectively. Additionally, the varying dose schedules allow flexibility in treatment, potentially reducing side effects and improving patient outcomes.

Research shows that pembrolizumab helps the immune system fight cancer and effectively treats colorectal cancer. Studies have found that pembrolizumab can extend patient survival and slow disease progression in certain types of colorectal cancer. Meanwhile, porustobart, when combined with another immunotherapy, has shown promising results. In one study, nearly 35% of patients experienced tumor shrinkage, and over 60% achieved some level of disease control. This trial will test two different dosing schedules of the combination of porustobart and pembrolizumab to determine its effectiveness in patients with microsatellite stable colon cancer, which is typically more challenging to treat with immunotherapy. The goal is for this combination to shrink tumors and enhance the immune system's ability to target the cancer.⁶⁷⁸⁹¹⁰